An AI model classifies risks of early relapse post-CAR T cell therapy in a multi-center real-world population with DLBCL

Using data drawn from multiple real-world centers, a newly developed artificial intelligence model can accurately classify the risk of early relapse in patients with DLBCL following CAR T-cell therapy. This tool offers clinicians a data-driven approach to identify high-risk individuals post-treatment, potentially guiding closer monitoring and individualized intervention strategies.